LuPIN Trial Interim Results Indicate Striking Survival Benefit

SYDNEY–(BUSINESS WIRE)–#GU20Noxopharm (ASX: NOX) is pleased to announce positive interim results from its LuPIN Phase 1/2 clinical trial. The data was presented during a poster presentation at the ASCO Genitourinary Cancers (GU) Symposium 2020 in San Francisco by St. Vincent’s Hospital Sydney.

The LuPIN study is being conducted by St. Vincent’s Hospital Sydney and is evaluating Noxopharm’s lead drug candidate, Veyonda®, in combination with 177Lu-PSMA-617, in 56 patients with late-stage metastatic castration-resistant prostate cancer (mCRPC).

“Today’s results are highly encouraging for patients, for Noxopharm shareholders, and for the St. Vincent’s Hospital Sydney team,” said Dr. Gisela Mautner, Noxopharm chief medical officer. “The study reported an unprecedented median overall survival of 17.1 months. In a patient group that normally would have a survival expectation of much less than this, such a result is astoundingly good. The combination treatment of Veyonda® and 177Lu-PSMA-617 has delivered a clinically meaningful and strong anti-cancer effect in a high proportion of men and, importantly, continues to have an excellent safety profile.”

All patients had received and failed two prior lines of therapy (chemotherapy and androgen-signaling inhibitors), and most patients (29 of 32) had failed a third line of therapy (another chemotherapy) prior to entering the trial.

“The study investigators at St. Vincent’s Hospital Sydney continue to do excellent work through the LuPIN trial and we are pleased to support them,” Dr. Mautner added.

“Being able to deliver a meaningful anti-cancer response for at least 50% of patients with Stage 4 for any form of cancer would be a remarkable outcome,” said Noxopharm CEO Dr. Graham Kelly. “But it is even more remarkable to do so in late-stage prostate cancer, where the disease typically involves a substantial number of secondaries in the skeleton, which are a significant and poorly accessible tumor load. A median overall survival of 17.1 months is remarkable for this novel radiosensitizing and immuno-oncology drug.”

About Noxopharm

Noxopharm is a clinical-stage Australian oncology drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in the non-oncology drug development company, Nyrada Inc. (ASX:NYR). Learn more at noxopharm.com.


Jane Byram

SCORR Marketing

(512) 626-2758

[email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.